Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Get Free Report) has received an average rating of “Moderate Buy” from the nineteen ratings firms that are presently covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and sixteen have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $245.9412.
JAZZ has been the subject of a number of research analyst reports. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $188.00 to $307.00 in a research report on Tuesday, May 19th. Robert W. Baird set a $252.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 6th. Leerink Partners boosted their target price on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 22nd. Weiss Ratings upgraded shares of Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, June 29th. Finally, Truist Financial decreased their price target on shares of Jazz Pharmaceuticals from $256.00 to $254.00 and set a “buy” rating on the stock in a research note on Tuesday.
View Our Latest Stock Report on Jazz Pharmaceuticals
Jazz Pharmaceuticals Price Performance
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last announced its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The firm had revenue of $1.07 billion for the quarter. Analysts expect that Jazz Pharmaceuticals will post 22.09 EPS for the current year.
Insider Activity at Jazz Pharmaceuticals
In other news, EVP Neena M. Patil sold 1,200 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total value of $278,196.00. Following the sale, the executive vice president directly owned 51,549 shares of the company’s stock, valued at $11,950,604.67. The trade was a 2.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $240.47, for a total value of $1,442,820.00. Following the sale, the director owned 366,682 shares of the company’s stock, valued at $88,176,020.54. The trade was a 1.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,098 shares of company stock worth $3,131,906 in the last quarter. Corporate insiders own 4.10% of the company’s stock.
Hedge Funds Weigh In On Jazz Pharmaceuticals
Several large investors have recently made changes to their positions in the stock. Ruffer LLP acquired a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at $2,425,000. Iron Triangle Partners LP purchased a new position in shares of Jazz Pharmaceuticals in the 3rd quarter valued at $19,770,000. Goldentree Asset Management LP acquired a new stake in shares of Jazz Pharmaceuticals in the third quarter valued at about $149,597,000. Faithward Advisors LLC boosted its position in Jazz Pharmaceuticals by 93.4% in the 3rd quarter. Faithward Advisors LLC now owns 27,904 shares of the specialty pharmaceutical company’s stock valued at $3,678,000 after buying an additional 13,475 shares during the last quarter. Finally, Allianz Asset Management GmbH raised its position in shares of Jazz Pharmaceuticals by 68.2% in the 4th quarter. Allianz Asset Management GmbH now owns 598,832 shares of the specialty pharmaceutical company’s stock valued at $101,801,000 after purchasing an additional 242,892 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.
Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.
Featured Articles
- Five stocks we like better than Jazz Pharmaceuticals
- Silicon Starvation: Amazon Feasts on Legacy GPUs
- GE Vernova’s Power Surge Turns the Grid Into an AI Trade
- Orbiting Capital: Lawmakers Buy SpaceX Ahead of Index Inclusion
- Big Beautiful Boycott: Can It Really Hurt Coca-Cola, Amazon, and Kraft Heinz Stocks?
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
